UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

13-5315170

(State of Incorporation)

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.05 par value

PFE

New York Stock Exchange

0.250% Notes due 2022

PFE22

New York Stock Exchange

1.000% Notes due 2027

PFE27

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

At August 3, 2020, 5,556,879,807 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended June 28, 2020 and June 30, 2019

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 28, 2020 and June 30, 2019

Condensed Consolidated Balance Sheets as of June 28, 2020 and December 31, 2019

Condensed Consolidated Statements of Equity for the three and six months ended June 28, 2020 and June 30, 2019

Condensed Consolidated Statements of Cash Flows for the six months ended June 28, 2020 and June 30, 2019

10

Notes to Condensed Consolidated Financial Statements

11

Report of Independent Registered Public Accounting Firm

45

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

46

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

98

Item 4.

Controls and Procedures

98

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

98

Item 1A.

Risk Factors

98

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

100

Item 3.

Defaults Upon Senior Securities

100

Item 4.

Mine Safety Disclosures

100

Item 5.

Other Information

100

Item 6.

Exhibits

101

Signature

102

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2019 Financial Report

Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019

2019 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2019

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

AML

Acute Myeloid Leukemia

Anacor

Anacor Pharmaceuticals, Inc.

Array

Array BioPharma Inc.

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CM

transthyretin amyloid cardiomyopathy

Bamboo

Bamboo Therapeutics, Inc.

BioNTech

BioNTech SE

Biopharma

Pfizer Biopharmaceuticals Group

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

cGMP

current Good Manufacturing Practices

COVID-19

novel coronavirus disease of 2019

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and

New Zealand

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),

Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development organization

GSK

GlaxoSmithKline plc

hGH-CTP

human growth hormone

Hospira

Hospira, Inc.

IBT

Income before tax

ICU Medical

ICU Medical, Inc.

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

J&J

Johnson & Johnson

JV

Joint Venture

King

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LDL

low density lipoprotein

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

MCO

managed care organization

mCRC

metastatic colorectal cancer

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation LLC (formerly Medivation, Inc.)

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

Mylan

Mylan N.V.

NDA

new drug application

NSCLC

non-small cell lung cancer

OPKO

OPKO Health, Inc.

PARP

poly ADP ribose polymerase

PBM

pharmacy benefit manager

Pharmacia

Pharmacia Corporation

PP&E

property, plant & equipment

PsA

psoriatic arthritis

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2020

RA

rheumatoid arthritis

RCC

renal cell carcinoma

R&D

research and development

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SI&A

selling, informational and administrative

S&P

Standard and Poor s

TCJA

legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Therachon

Therachon Holding AG

UC

ulcerative colitis

U.K.

United Kingdom

U.S.

United States

Valneva

Valneva SE

ViiV

ViiV Healthcare Limited

VBP

Volume-based procurement

WRDM

Worldwide Research, Development and Medical

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

June 28,

2020

June 30,

2019

June 28,

2020

June 30,

2019

Revenues

11,801

13,264

23,829

26,382

Costs and expenses:

Cost of sales(a)

2,281

2,576

4,658

5,009

Selling, informational and administrative expenses(a)

3,030

3,511

5,903

6,850

Research and development expenses(a)

2,132

1,842

3,856

3,544

Amortization of intangible assets

905

1,184

1,790

2,367

Restructuring charges and certain acquisition-related costs

362

(115

431

(69

(Gain) on completion of Consumer Healthcare JV transaction

(6

Other (income)/deductions net

(862

126

(641

218

Income from continuing operations before provision/(benefit) for taxes on income

3,953

4,141

7,838

8,463

Provision/(benefit) for taxes on income

519

(915

993

(481

Income from continuing operations

3,434

5,056

6,845

8,945

Discontinued operations net of tax

Net income before allocation to noncontrolling interests

3,434

5,056

6,845

8,945

Less: Net income attributable to noncontrolling interests

10

17

15

Net income attributable to Pfizer Inc.

3,426

5,046

6,828

8,929

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.62

0.91

1.23

1.59

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.62

0.91

1.23

1.59

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.61

0.89

1.22

1.56

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.61

0.89

1.22

1.56

Weighted-average shares basic

5,554

5,562

5,550

5,598

Weighted-average shares diluted

5,619

5,672

5,616

5,711

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

June 28,

2020

June 30,

2019

June 28,

2020

June 30,

2019

Net income before allocation to noncontrolling interests

3,434

5,056

6,845

8,945

Foreign currency translation adjustments, net(a)

(242

(485

(1,513

(161

Reclassification adjustments

(242

(485

(1,513

(159

Unrealized holding gains/(losses) on derivative financial instruments, net

213

(176

(288

91

Reclassification adjustments for gains included in net income(b)

(186

(81

(167

(343

27

(256

(455

(252

Unrealized holding gains/(losses) on available-for-sale securities, net

42

(7

(9

33

Reclassification adjustments for losses included in net income(c)

44

26

59

37

87

19

50

70

Benefit plans: actuarial gains/(losses), net

(4

(160

(4

Reclassification adjustments related to amortization

67

60

133

121

Reclassification adjustments related to settlements, net

13

66

Other

68

41

84

18

153

100

122

137

Benefit plans: prior service costs and other, net

(1

(1

Reclassification adjustments related to amortization of prior service costs and other, net

(45

(46

(89

(93

Other

(40

(46

(85

(92

Other comprehensive loss, before tax

(14

(669

(1,882

(296

Tax provision/(benefit) on other comprehensive loss

113

(59

(265

(34

Other comprehensive loss before allocation to noncontrolling interests

(127

(610

(1,617

(262

Comprehensive income before allocation to noncontrolling interests

3,307

4,446

5,227

8,683

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(4

12

13

Comprehensive income attributable to Pfizer Inc.

3,312

4,434

5,222

8,669

(a)

Amounts in the second quarter of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a gain of approximately $380 million pre-tax ($291 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in the first six months of 2020 include a loss of approximately $1.2 billion pre-tax ($902 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see Note 2B. Acquisition, Equity-Method Investment and Licensing Arrangements: Equity-Method Investment.

(b)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(c)

Reclassified into Other (income)/deductions net.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

June 28,

2020

December 31,

2019

(Unaudited)

Assets

Cash and cash equivalents

1,801

1,305

Short-term investments

9,581

8,525

Restricted short-term investments(a)

11,412

Trade accounts receivable, less allowance for doubtful accounts: 2020 $525; 2019 $527

9,128

8,724

Inventories

8,564

8,283

Current tax assets

3,426

3,344

Other current assets

2,513

2,622

Total current assets

46,424

32,803

Equity-method investments

15,578

17,133

Long-term investments

3,142

3,014

Property, plant and equipment, less accumulated depreciation: 2020 $16,889; 2019 $16,789

14,113

13,967

Identifiable intangible assets, less accumulated amortization

33,541

35,370

Goodwill

58,449

58,653

Noncurrent deferred tax assets and other noncurrent tax assets

2,360

2,099

Other noncurrent assets

4,327

4,450

Total assets

177,934

167,489

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2020 $1,481; 2019 $1,462

13,084

16,195

Trade accounts payable

3,872

4,220

Dividends payable

2,111

2,104

Income taxes payable

1,445

980

Accrued compensation and related items

2,042

2,720

Other current liabilities

10,168

11,083

Total current liabilities

32,723

37,304

Long-term debt(a)

50,529

35,955

Pension benefit obligations, net

5,344

5,638

Postretirement benefit obligations, net

1,086

1,124

Noncurrent deferred tax liabilities

5,409

5,578

Other taxes payable

11,468

12,126

Other noncurrent liabilities

6,812

6,317

Total liabilities

113,370

104,042

Commitments and Contingencies

Preferred stock

17

Common stock

470

468

Additional paid-in capital

87,886

87,428

Treasury stock

(110,978

(110,801

Retained earnings

100,203

97,670

Accumulated other comprehensive loss

(13,246

(11,640

Total Pfizer Inc. shareholders equity

64,336

63,143

Equity attributable to noncontrolling interests

228

303

Total equity

64,564

63,447

Total liabilities and equity

177,934

167,489

(a)

The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see Note 7D. Financial Instruments: Long-Term Debt.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, March 29, 2020

417

17

9,393

470

87,680

(3,841

(111,010

101,000

(13,131

65,026

312

65,338

Net income

3,426

3,426

3,434

Other comprehensive income/(loss), net of tax

(115

(115

(12

(127

Cash dividends declared:

Common stock

(4,223

(4,223

(4,223

Preferred stock

Noncontrolling interests

(80

(80

Share-based payment transactions

221

222

222

Purchases of common stock

Preferred stock conversions and redemptions(a)

(417

(17

(14

31

Other

Balance, June 28, 2020

9,394

470

87,886

(3,840

(110,978

100,203

(13,246

64,336

228

64,564

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, March 31, 2019

466

19

9,358

468

86,635

(3,801

(110,781

93,388

(10,923

58,806

352

59,158

Net income

5,046

5,046

10

5,056

Other comprehensive income/(loss), net of tax

(613

(613

(610

Cash dividends declared:

Common stock

(3,994

(3,994

(3,994

Preferred stock

Noncontrolling interests

(8

(8

Share-based payment transactions

329

(6

324

324

Purchases of common stock

Preferred stock conversions and redemptions

(8

(1

(1

(1

Other

Balance, June 30, 2019

458

18

9,363

468

86,963

(3,801

(110,786

94,440

(11,535

59,568

357

59,924

See end of tables for notes.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value